Name: Eli Lilly & Co. (NYSE:LLY) | Analysis of Revenues
Creator: Stock Analysis on Net

Analysis of Revenues

Eli Lilly & Co., income statement, revenues

US$ in thousands

12 months ended:	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Diabetes and obesity	19,667,600)	14,464,800)	13,188,100)	11,834,400)	11,132,100)
Oncology	6,658,300)	5,666,200)	5,741,300)	5,319,300)	4,614,400)
Immunology	3,797,500)	3,344,600)	3,360,800)	2,461,900)	1,793,300)
Neuroscience	2,878,500)	1,546,200)	1,898,500)	1,831,300)	1,722,900)
Other human pharmaceutical products	1,122,200)	3,519,600)	4,129,900)	3,092,800)	3,056,800)
Revenue	34,124,100)	28,541,400)	28,318,600)	24,539,700)	22,319,500)

Download chart

Item	Description	The company
Revenue	Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).	Eli Lilly & Co. revenue increased from 2021 to 2022 and from 2022 to 2023.